Accumulated genomic studies in leiomyomas have indicated the existence of genetic heterogeneity in these tumors, including chromosomal rearrangements and gene mutation such as HMGA2 (high-mobility group AT-hook 2), COL4A5/6 (collagen, type IV, alpha 5 and alpha 6), MED12 (mediator complex subunit 12), and FH (fumarate hydratase), which may be related to leiomyoma development and progression [8,9,10]. The gene discussed is MED12; the disease is leiomyoma.